Itulazax (Betula Verrucosa (108))

• Itulazax is used in allergy immunotherapy to address IgE‑mediated reactions to birch pollen.
• Allergic rhinitis: reduces nasal congestion, sneezing and itching caused by Betula verrucosa pollen.
• Allergic conjunctivitis: alleviates eye redness, itching and tearing associated with birch pollen exposure.
• Seasonal allergic rhinoconjunctivitis: provides sustained symptom control throughout the birch pollen season.

• Sublingual administration of Betula verrucosa extract delivers controlled allergen exposure to oral mucosal immune cells, promoting regulatory T‑cell development and IgG4 blocking antibody production while shifting the Th2‑dominant response toward a tolerant Th1 profile, thereby reducing IgE‑mediated allergic inflammation.

Adverse reactions to Itulazax are generally related to local immune activation in the oral cavity and systemic allergic responses.

Common Side Effects

• Oral itching: mild irritation of the mouth or throat after dosing.
• Throat irritation: transient discomfort in the throat.
• Nasal congestion: temporary blockage of nasal passages.

Serious or Rare Side Effects

• Anaphylaxis: severe, potentially life‑threatening allergic reaction.
• Angioedema: swelling of lips, tongue or face.
• Severe bronchospasm: acute narrowing of airways causing breathing difficulty.

• When prescribing Itulazax, clinicians should consider several safety measures.
• Patient selection: confirm IgE‑mediated Betula verrucosa allergy before initiating therapy.
• Initial dosing: start with a low sublingual dose under medical supervision.
• Monitoring: observe for at least 30 minutes after first administration for systemic reactions.
• Contraindications: avoid in patients with a history of severe anaphylaxis to birch pollen.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; data limited.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and direct sunlight.

Itulazax may interact with other medications that affect allergic response or immune modulation.

Major Interactions (Avoid)

• Concurrent use of beta‑blockers: may mask symptoms of anaphylaxis and complicate treatment.
• ACE inhibitors: increase risk of angioedema during allergic reactions.

Moderate Interactions (Monitor Closely)

• Antihistamines: may reduce efficacy of sublingual immunotherapy if taken shortly before dosing.
• Corticosteroids: may alter immune response, requiring dose adjustment.
• Other allergen extracts: simultaneous administration can increase risk of systemic reactions.